Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study reveals best ways to adjust ulcerative colitis treatment for better living

NCT ID NCT05271773

Knowledge-focused Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 234 adults with ulcerative colitis whose gut lining had healed (Mayo 0 or 1). Researchers tracked how increasing, decreasing, or switching treatments affected patients' quality of life over 6 and 12 months. They also measured inflammation markers like fecal calprotectin. The goal was to find the best treatment approach for maintaining well-being.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

234 people

The number who actually took part.

Started

Nov 2022

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with an established diagnosis of UC through regular criteria (clinical, analytical, endoscopic, radiological and/or histological ones), in clinical remission (partial Mayo score ≤2) for at least three months, who had undergone surveillance colonoscopy after 12 months from the study outset, with a Mayo 0 or Mayo 1 endoscopic activity.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * UC diagnosed. * Age ≥ 18. * Signed and dated informed consent form. * Have undergone a Mayo 0 or 1 endoscopic score colonoscopy while in clinical remission. Exclusion Criteria: * Incomplete colonoscopy. * Previous bowel resection. * Ostomy patient. * Active infection. * Pregnancy. * Lack of patient's informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IBD (inflammatory bowel disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IBD (inflammatory bowel disease) Uc - ulcerative colitis

Contacts and locations

Locations

  • Hospital Marqués de Valdecilla

    Santander, Cantabria, 39008, Spain

  • Hospital Universitari Parc Taulí

    Sabadell, Catalonia, 08208, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hospital Universitario La Princesa

    Madrid, 28006, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, 28034, Spain

  • Hospital Universitario de Canarias

    San Cristóbal de La Laguna, Santa Cruz De Tenerife, 38018, Spain

  • Hospital Universitario de Cáceres

    Cáceres, Extremadura, 10004, Spain

  • Hospital Universitario de Santiago de Compostela

    Santiago de Compostela, Galicia, 15706, Spain

  • Hospital Universitario. Miguel Servet

    Zaragoza, 50009, Spain

  • Hospital de Santa Bárbara de Puertollano

    Puertollano, Ciudad Real, 13500, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.